Published in Vaccine Weekly, September 5th, 2001
L.F. Fries and colleagues tested the vaccine, comprising native S. flexneri 2a lipopolysaccharide (LPS) complexed to meningococcal outer membrane proteins, in a dose-escalating series of two immunizations. Doses were 0.1, 0.4, 1.0, and 1.5 mg based on protein.
The vaccine elicited S. flexneri* 2a LPS-specific immunoglobulin A (IgA), IgG, and IgM antibody-secreting cells (ASCs)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.